Selected Publications
Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS, Karam C.: Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study Orphanet J Rare Dis. : 2024 .
Jones FJS, Zager E, Karam C.: Clinical Reasoning: A 61-Year-Old Man With Progressive Right Leg Numbness and Weakness. Neurology. 2024 Oct 22;103(8):e209900 : 2024.
Jones FJS, Cohen AD, Karam C.: Clinical Reasoning: A 49-Year-Old Man With Progressive Numbness, Gait Instability, and Tremors Neurology. 103(7) : 2024.
Jones FJS, Cohen AD, Karam C.: Clinical Reasoning: A 49-Year-Old Man With Progressive Numbness, Gait Instability, and Tremors Neurology. 2024 Oct 8;103(7):e209879. : 2024.
Berth SH, Vo L, Kwon DH, Grider T, Damayanti YS, Kosmanopoulos G, Fox A, Lau AR, Carr P, Donohue JK, Hoke M, Thomas S, Karam C, Fay AJ, Meltzer E, Crawford TO, Gaudet R, Shy ME, Hellmich UA, Lee SY, Sumner CJ, McCray BA.: Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants. Brain. : 2024.
Jones FJS, Singer M, Zager E, Karam C.: Mononeuropathy Due to Inflammatory Pseudotumor of Nerve Neurology. : 2024.
Pottinger TD, Motelow JE, Povysil G, Moreno CAM, Ren Z, Phatnani H; New York Genome Center ALS Sequencing Consortium; Aitman TJ, Santoyo-Lopez J; Scottish Genomes Partnership; Mitsumoto H; ALS COSMOS Study Group; PLS COSMOS Study Group; GTAC Investigators; Goldstein DB, Harms MB. Rare: Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS.
BMC Genomics. : 2024.
Traub R, Qarni T, Cohen AD, Karam C.: Paraproteinemic neuropathies Muscle Nerve. : 2024.
Berends M, Nienhuis HLA, Adams D, Karam C, Luigetti M, Polydefkis M, Reilly MM, Sekijima Y, Hazenberg BPC.: Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review Int J Mol Sci. : 2024.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, De Bleecker JL, Murai H, Meisel A, Beydoun SR, Pasnoor M, Guglietta A, Van Hoorick B, Steeland S, T'joen C, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT+ Study Group.: Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis Front. Neurol. : 2024.
View all publications
Academic Contact Information
3400 Spruce St., 3 West Gates
Philadelphia,
PA
19104
Phone: 215-615-3751
Patient appointments: 800-789-7366